2.1. Study Design and Patients
Dupilumab, asthma
ASTHMA
QUEST was a phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial evaluating the safety and efficacy of dupilumab in patients aged ≥12 years with uncontrolled, moderate-to-severe asthma. Dupilumab is approved in the USA as an add-on maintenance treatment in patients with moderate-to-severe asthma aged ≥6 years with an eosinophilic phenotype or with oral corticosteroid-dependent asthma, and in Europe to treat patients with uncontrolled, severe asthma aged ≥6 years [Only patients with type 2 asthma (defined as having baseline blood eosinophils ≥ 150 cells/